Demographic and clinical findings over time
| Parameter n (%), median (IQR) | Baseline n (%) | 6 months n (%) | 12 months n (%) | 18 months n (%) | 24 months n (%) | 30 months n (%) | 36 months n (%) | 42 months n (%) | 48 months n (%) | 54 months n (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Total | 258 (100) | 258 (100) | 249 (97) | 224 (87) | 201 (78) | 128 (50) | 97 (38) | 86 (33) | 70 (27) | 49 (19) |
| Male | 138 (53) | 138 (53) | 131 (53) | 118 (53) | 109 (54) | 63 (49) | 48 (49) | 42 (49) | 35 (50) | 22 (45) |
| Age in months | 28 (13–51) | 33 (19–56) | 39 (25–62) | 45 (30–70) | 50 (34–75) | 52 (40–73) | 60 (47–76) | 64 (52–83) | 70 (59–89) | 79 (65–96) |
| On ART | 70 (27) | 115 (45) | 159 (64) | 163 (73) | 157 (78) | 101 (82) | 80 (82) | 71 (83) | 58 (83) | 38 (78) |
| CD4+% | 21 (15–28) | 21 (15–29) | 24 (18–30) | 25 (18–31) | 27 (20–33) | 26 (20–32) | 27 (21–34) | 29 (23–35) | 30 (25–37) | 32 (25–35) |
| Weight-for-age z-score <2 | 84 (33) | 73 (28) | 62 (25) | 43 (19) | 33 (16) | 18 (14) | 15 (15) | 14 (16) | 11 (16) | 9 (18) |
| PTB diagnosed in period | 37 (14) | 16 (6) | 11 (4) | 5 (2) | 0 | 2 (1) | 1 (0) | 1 (0) | 0 | 0 |
| Hospitalised in period | n/a | 48 (19) | 34 (13) | 11 (4) | 9 (3) | 3 (1) | 5 (2) | 1 (0) | 0 | 0 |
| CDC clinical category | ||||||||||
| N | 3 (1) | 2 (1) | 2 (1) | 0 (0) | 0 | 0 | 0 | 0 | 0 | 0 |
| A | 22 (9) | 12 (5) | 10 (4) | 4 (2) | 2 | 0 | 0 | 0 | 0 | 0 |
| B | 163 (63) | 158 (61) | 145 (58) | 127 (57) | 109 (54) | 56 (44) | 45 (46) | 36 (42) | 26 (37) | 16 (33) |
| C | 70 (27) | 86 (33) | 92 (37) | 93 (42) | 90 | 72 (56) | 52 (54) | 50 (58) | 44 (63) | 33 (67) |
ART, antiretroviral therapy; CDC, Centres for Disease Control and Prevention; PTB, pulmonary TB.